title: Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: T
authors.initials: T
authors.lastname: Hideshima
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: N
authors.initials: N
authors.lastname: Mimura
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Minami
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: H
authors.initials: H
authors.lastname: Ohguchi
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kikuchi
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: G
authors.initials: G
authors.lastname: Gorgun
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Cirstea
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: F
authors.initials: F
authors.lastname: Cottini
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Jakubikova
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Y-T
authors.initials: YT
authors.lastname: Tai
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Chauhan
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: P G
authors.initials: PG
authors.lastname: Richardson
authors.affiliation: VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: N C
authors.initials: NC
authors.lastname: Munshi
authors.affiliation: Tsukuba Research Center, TAIHO PHARMACEUTICAL CO. LTD., Tsukuba, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Utsugi
authors.affiliation: Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis; D001549:Benzamides / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D004354:Drug Screening Assays, Antitumor; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D020559:Monomeric GTP-Binding Proteins / Q000378:metabolism; D009101:Multiple Myeloma / Q000188:drug therapy*; D009154:Mutation; D009368:Neoplasm Transplantation; D011719:Pyrazines / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D055213:Retinal Pigment Epithelium / Q000166:cytology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001897:Boronic Acids; D000069286:Bortezomib; D018841:HSP90 Heat-Shock Proteins; D020559:Monomeric GTP-Binding Proteins; D011719:Pyrazines; D011720:Pyrazoles; C533585:HSP90AA2P protein, human; C493165:HSP90AB1 protein, human; C000596495:pimitespib; C586503:Nras protein, mouse